Trulicity Cost in Minnesota 2026: Prices, Insurance, Medicaid, and Alternatives

What Is the Actual Cash Price of Trulicity in Minnesota in 2026?

The Eli Lilly wholesale acquisition cost for Trulicity is $931 per month for any of the four available doses (0.75 mg, 1.5 mg, 3 mg, or 4.5 mg). Without insurance or a savings program, Minnesota retail pharmacies charge close to that figure. GoodRx and similar coupon platforms typically return prices between $840 and $931 at chains including CVS, Walgreens, and Walmart Pharmacy across the Twin Cities metro and greater Minnesota.

That price reflects a four-pen carton covering four weekly injections. Patients who need dose escalation from 0.75 mg to 1.5 mg pay the same carton price because Eli Lilly prices by pack, not by dose strength. The 3 mg and 4.5 mg strengths, approved in 2020 to improve glycemic control, carry the same list price as well.

Cash price is rarely the price a patient actually pays. Employer-sponsored plans, state Medicaid, Medicare Part D, and manufacturer savings programs each change the arithmetic significantly. The sections below address each pathway in detail.

Dulaglutide's FDA label was first approved on September 18, 2014, for glycemic control in adults with type 2 diabetes, with a later label expansion in 2020 to include reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [1] That cardiovascular indication matters for coverage decisions because payers sometimes tier GLP-1 receptor agonists differently when a CV outcome benefit is documented in a labeled indication.

The REWIND trial (N=9,901, median follow-up 5.4 years) demonstrated a 12% relative risk reduction in the composite MACE endpoint (HR 0.88 to 95% CI 0.79, 0.99, P<0.026) for dulaglutide 1.5 mg once weekly versus placebo in patients with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors. [2] Payers use that data when writing formulary policy for GLP-1 agents.

Does Minnesota Medicaid Cover Trulicity?

Minnesota Medicaid (called Medical Assistance, or MA) covers Trulicity for adults with type 2 diabetes, but only after a prior authorization (PA) is approved. The PA requirement is standard across most state Medicaid programs for branded GLP-1 receptor agonists. [3]

To obtain PA under Minnesota Medical Assistance, prescribers generally must document that the patient has a confirmed diagnosis of type 2 diabetes, that metformin or another first-line agent was tried and either failed or was contraindicated, and that the patient meets body mass index or A1c thresholds defined in the current MA preferred drug list criteria. Specific thresholds can shift with each annual PDL update, so clinicians should verify current criteria through the Minnesota Department of Human Services (DHS) provider portal before submitting a PA request.

Minnesota also operates MinnesotaCare, a subsidized program for residents who earn too much for full Medicaid but cannot afford private coverage. MinnesotaCare uses the same Medical Assistance pharmacy benefit and the same prior authorization process for Trulicity. Patients enrolled through MNsure in a qualified health plan (QHP) are subject to their plan's individual formulary rather than the MA PDL.

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line agents after metformin in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. [4] That guideline recommendation strengthens PA appeal arguments when initial requests are denied.

Medicaid beneficiaries denied PA have the right to a state fair hearing. Providing the REWIND trial data and the ADA guideline recommendation alongside the PA request can reduce the need for appeals.

How Do Commercial Insurance Plans Cover Trulicity in Minnesota?

Most commercial plans sold in Minnesota place Trulicity on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. Tier placement determines the patient's copay or coinsurance obligation after meeting the deductible.

Large employers in Minnesota that use pharmacy benefit managers (PBMs) such as Express Scripts, OptumRx, or CVS Caremark tend to follow national formulary templates. On the Express Scripts National Preferred Formulary, dulaglutide has historically appeared as a covered brand with quantity limits tied to the FDA-approved once-weekly dosing schedule. [5] OptumRx and CVS Caremark maintain similar coverage, though specific tier placement varies by employer contract.

Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, and UCare are the four largest fully insured carriers in the state. Each publishes an annual formulary through its provider and member portal. Patients should confirm their plan year's Tier and PA requirements before January 1 each year, because formulary changes take effect annually.

Step therapy is common. Many Minnesota plans require that a patient try a generic GLP-1 option or another antidiabetic class first, though the availability of generic dulaglutide in 2026 remains limited. The FDA has not approved a generic or biosimilar for dulaglutide as of early 2025. [1] That absence of a generic equivalent means step therapy protocols typically require only a trial of metformin or a sulfonylurea before approving the branded agent.

How Does the Eli Lilly Savings Card Work for Minnesota Patients?

Eli Lilly offers a commercial savings card (sometimes called the Trulicity Savings Card) that allows eligible commercially insured patients in Minnesota to pay a reduced copay. The card cannot be used with Medicare, Medicaid, TRICARE, or any other federally funded program. [6]

Under the current program, eligible patients with commercial insurance may pay as little as $25 to $150 per month depending on their plan's cost-sharing structure. The savings card covers the gap between the plan's cost-sharing requirement and the program cap. Patients enroll at LillyInsulin.com or through the Lilly Cares Foundation portal; income verification is not required for the commercial card, only confirmation of private insurance.

Patients who are uninsured or who lose insurance coverage may qualify instead for the Lilly Cares Patient Assistance Program, which provides Trulicity at no cost to patients meeting income eligibility criteria (typically at or below 400% of the federal poverty level). [6] Minnesota residents can apply directly through the Lilly Cares website or through a HealthRX care navigator.

The savings card does not reduce the amount Lilly charges the insurer. It reduces only the patient's out-of-pocket share. Some employers have begun excluding GLP-1 savings cards from their benefit design through "copay accumulator" or "copay maximizer" programs, which means the card payments may not count toward a patient's deductible. Minnesota has not enacted state legislation restricting copay accumulator programs as of the 2025 legislative session, so patients should ask their HR department whether their plan uses an accumulator.

Is Compounded Dulaglutide Legal in Minnesota?

Compounded dulaglutide occupies a contested regulatory space in Minnesota in 2026. The short answer: 503A compounding pharmacies licensed in Minnesota may compound dulaglutide under specific federal shortage and compounding law provisions, but this status is not permanent and is subject to FDA enforcement discretion. [7]

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound drugs based on a valid patient-specific prescription when the drug appears on the FDA's drug shortage list or meets other criteria. Dulaglutide was added to shortage-adjacent discussions during the broader GLP-1 supply disruption of 2023 to 2024. Compounding pharmacies in Minnesota, including several in the Twin Cities metro, began offering compounded dulaglutide injections during that period.

The FDA has issued guidance warning that compounded GLP-1 products, including semaglutide and dulaglutide analogs, may not meet the same safety and efficacy standards as the FDA-approved drug. [7] The agency has also stated that compounded versions using salt forms of semaglutide (semaglutide sodium, semaglutide acetate) are not the same active ingredient as the approved drug, and it has applied similar scrutiny to dulaglutide analogs.

The Minnesota Board of Pharmacy licenses 503A compounding pharmacies and enforces state compounding law, which generally aligns with federal USP standards. Patients receiving compounded dulaglutide from a licensed Minnesota 503A pharmacy are receiving a pharmacy-compounded product, not an FDA-approved biologic. Risks include unknown sterility, underdosing, overdosing, and lack of pharmacokinetic data for the compounded formulation. [8]

HealthRX medical reviewers apply a three-step framework when evaluating compounded dulaglutide for a Minnesota patient: (1) confirm the prescribing pharmacy holds an active Minnesota 503A license; (2) verify the pharmacy uses USP 797 sterile compounding standards with documented third-party potency and sterility testing; (3) document in the chart that the patient was counseled on the difference between compounded and FDA-approved dulaglutide before initiating therapy. Patients who can access branded Trulicity at an equivalent or lower net cost through insurance or savings programs should be offered that option first.

Can Minnesota Patients Get Trulicity via Telehealth?

Yes. Minnesota permits telehealth prescribing of non-controlled substances, and dulaglutide is not a controlled substance. [9] A licensed Minnesota prescriber (MD, DO, PA, or NP with appropriate prescriptive authority) may evaluate a patient via synchronous audio-video telehealth and issue a valid Trulicity prescription that any Minnesota pharmacy can fill.

The DEA's special telehealth registration for controlled substances does not apply to GLP-1 receptor agonists. Prescribers using HealthRX or another telehealth platform only need to hold an active Minnesota medical license and comply with Minnesota's telemedicine statute (Minn. Stat. sec. 62A.671), which requires that the prescriber conduct an appropriate clinical evaluation before initiating therapy. A purely asynchronous questionnaire without a synchronous encounter does not meet that standard for a new Trulicity prescription under current Minnesota telemedicine law.

The REWIND trial established that dulaglutide reduces MACE risk over a median 5.4-year follow-up in patients with type 2 diabetes aged 50 and older, with a mean baseline A1c of 7.3% and 31% of participants having no prior cardiovascular disease. [2] That evidence base means telehealth clinicians can appropriately initiate Trulicity for primary prevention in high-risk diabetic patients, not only for those with established cardiovascular disease.

Telehealth encounters for Trulicity in Minnesota typically take 20 to 30 minutes for a new patient visit. Lab requirements before initiation generally include a recent A1c (within 90 days), basic metabolic panel, and lipid panel. The prescriber must also screen for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as noted in the boxed warning on the FDA label. [1]

What Is the Cheapest Way to Get Trulicity in Minnesota?

The lowest net cost for most Minnesota patients follows one of three paths, depending on insurance status.

Commercially insured patients with an employer or ACA marketplace plan should stack the Lilly savings card on top of their insurance benefit. Net cost can fall to $25 per month if the plan's cost-sharing is above that floor and the employer has not implemented a copay accumulator. [6]

Medicaid-enrolled patients pay nothing out of pocket for Trulicity once prior authorization is approved. Medical Assistance pharmacy benefits have no copay for most beneficiaries at the standard income level. Navigating the PA process quickly is the main barrier, and many Minnesota patient assistance programs or hospital social workers can help. [3]

Uninsured patients with household income at or below 400% of the federal poverty level should apply for the Lilly Cares Patient Assistance Program before considering compounded alternatives. Approval typically takes two to four weeks, and the program ships directly to the patient's home or prescriber's office. [6]

GoodRx coupons at Minnesota pharmacies offer discounts from the retail price but still leave most uninsured patients paying $840 to $931 per month, which is not truly affordable for the majority of residents without other assistance. Compounded dulaglutide from a licensed 503A pharmacy may approach zero net cost in some arrangements, though the regulatory risks described above apply.

A 2023 JAMA Internal Medicine analysis found that list prices for GLP-1 receptor agonists in the United States are approximately eight times higher than prices for the same drugs in comparable high-income countries. [10] That disparity has driven significant interest in compounding and importation, but Minnesota patients should be aware that personal importation of Trulicity from Canada or elsewhere violates federal law under the Food, Drug, and Cosmetic Act, and the FDA does not routinely exercise enforcement discretion for injectable biologics as it does for some oral drugs.

How Dulaglutide Compares to Other GLP-1 Options Available in Minnesota

Minnesota patients and prescribers often compare Trulicity to semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) on both cost and efficacy grounds. The SUSTAIN-7 head-to-head trial (N=1,201) showed that semaglutide 0.5 mg and 1.0 mg produced greater A1c reductions and weight loss than dulaglutide 0.75 mg and 1.5 mg respectively over 40 weeks (P<0.001 for both A1c and body weight comparisons). [11] Semaglutide 1.0 mg reduced A1c by 1.8% versus 1.4% for dulaglutide 1.5 mg, and reduced body weight by 6.5 kg versus 3.0 kg.

However, dulaglutide's clinical profile still positions it as a strong option for patients who prioritize the ease of the single-use autoinjector device, who cannot tolerate semaglutide side effects, or whose insurance tier places Trulicity at a lower cost share than Ozempic. The REWIND cardiovascular outcome data at the 1.5 mg dose, which is the dose studied, give clinicians a labeled cardiovascular risk reduction claim that guides prescribing in patients aged 50 and older with diabetes and at least one cardiovascular risk factor. [2]

Liraglutide (Victoza) carries a lower list price in some Minnesota pharmacy markets due to greater generic competition pressure, though no generic liraglutide was FDA-approved as of early 2025. [12] The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced MACE by 13% versus placebo (HR 0.87 to 95% CI 0.78, 0.97, P<0.001 for non-inferiority, P=0.01 for superiority) in high-risk patients with type 2 diabetes. [12]

Formulary placement at the four major Minnesota carriers shifts annually, so comparing Tier assignments for dulaglutide versus semaglutide at open enrollment each fall is a practical cost-reduction step for patients whose diabetes management goals are achievable with either agent.

Monitoring and Dose Escalation Considerations for Minnesota Prescribers

Trulicity is initiated at 0.75 mg once weekly for at least four weeks before escalating to 1.5 mg. Further escalation to 3 mg and then 4.5 mg occurs in four-week intervals if additional glycemic control is needed. [1] The FDA label does not recommend doses above 4.5 mg per week.

A1c should be checked at baseline, three months after initiation or any dose change, and every six months once stable, consistent with ADA monitoring standards. [4] Renal function does not require dose adjustment for dulaglutide, though the drug should be used with caution in patients with severely impaired renal function (eGFR <15 mL/min/1.73 m2) given limited clinical data in that population per the prescribing information. [1]

Gastrointestinal side effects (nausea, diarrhea, vomiting, decreased appetite) occur in up to 21% of patients at the 1.5 mg dose in clinical trials and are the primary reason for discontinuation. [1] Slower escalation over eight rather than four weeks per dose step may reduce GI burden, a strategy supported by clinical practice experience though not formally studied in a dedicated RCT.

Thyroid C-cell tumor risk, observed in rodent studies, carries the boxed warning on the Trulicity label. The FDA states: "It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." [1] Patients with a personal or family history of MTC or MEN2 must not receive dulaglutide.

Pancreatitis has been reported in GLP-1 receptor agonist trials. The REWIND trial did not show a statistically significant increase in pancreatitis events with dulaglutide versus placebo, though cases occurred in both arms. [2] Clinicians should discontinue Trulicity if pancreatitis is suspected and not restart it after confirmation.

Minnesota prescribers operating via telehealth should arrange for local lab monitoring at a LabCorp, Quest, or health system outpatient lab accessible to the patient, as remote management of dose escalation without periodic A1c review does not meet the ADA standard of care for ongoing diabetes management. [4]